AR064262A1 - Composiciones farmaceuticas liquidas que comprenden un compuesto bisfosfonato - Google Patents

Composiciones farmaceuticas liquidas que comprenden un compuesto bisfosfonato

Info

Publication number
AR064262A1
AR064262A1 ARP070105120A ARP070105120A AR064262A1 AR 064262 A1 AR064262 A1 AR 064262A1 AR P070105120 A ARP070105120 A AR P070105120A AR P070105120 A ARP070105120 A AR P070105120A AR 064262 A1 AR064262 A1 AR 064262A1
Authority
AR
Argentina
Prior art keywords
optionally
liquid pharmaceutical
amount
therapeutic use
bisphosphonate
Prior art date
Application number
ARP070105120A
Other languages
English (en)
Original Assignee
Besins Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06291785A external-priority patent/EP1923049A1/en
Priority claimed from EP06291786A external-priority patent/EP1923050A1/en
Application filed by Besins Healthcare filed Critical Besins Healthcare
Publication of AR064262A1 publication Critical patent/AR064262A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones farmacéuticas líquidas que comprenden un compuesto bisfosfonato para administracion topica. Reivindicacion 1: Una composicion farmacéutica líquida para administracion a la piel humana que comprende: (1) una cantidad efectiva para uso terapéutico de al menos un bisfosfonato (ii) opcionalmente, una cantidad irritante de al menos un humectante con preferencia glicerina, (iii) opcionalmente, al menos un alcohol alifático de cadena rota, (iv) opcionalmente, al menos un tensioactivo y (v) agua, donde dicha composicion: es una mezcla estable, microscopicamente homogénea, tiene un pH de entre 4,0 y 8,5 y no contienen ningun gelante y es no oclusiva y no forma película. Reivindicacion 16: El dispositivo de la cualquiera de las Reivindicaciones 12-15, donde el aplicador comprende un aplicador seleccionado del grupo que consiste en un gotero, pipeta, hisopo, cepillo, pano, almohadilla, esponja y soporte solido. Reivindicacion 22: Un método para tratar un trastorno relacionado con los huesos, que comprende la administracion topica a una superficie de la piel de un paciente necesitado de la misma, de una cantidad efectiva para uso terapéutico de una composicion farmacéutica líquida que comprende: (i) una cantidad efectiva para uso terapéutico de al menos un bisfosfonato, (ii) opcionalmente, una cantidad no irritante de al menos un humectante con preferencia glicerina, (iii) opcionalmente al menos un alcohol alifático de cadena corta, (iv) opcionalmente, al menos un tensioactivo y (v) agua donde dicha composicion : es una mezcla estable, microscopicamente homogénea, tiene un pH de entre 4,o y 8,5, no contiene ningun agente gelante, es no oclusiva y no forma película, y se adapta para administracion topica a la superficie de la piel.
ARP070105120A 2006-11-17 2007-11-16 Composiciones farmaceuticas liquidas que comprenden un compuesto bisfosfonato AR064262A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86629406P 2006-11-17 2006-11-17
US86630606P 2006-11-17 2006-11-17
EP06291785A EP1923049A1 (en) 2006-11-17 2006-11-17 Pharmaceutical compositions comprising a bisphosphonate compound
EP06291786A EP1923050A1 (en) 2006-11-17 2006-11-17 Liquid pharmaceutical compositions comprising a bisphosphonate compound

Publications (1)

Publication Number Publication Date
AR064262A1 true AR064262A1 (es) 2009-03-25

Family

ID=38895592

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070105120A AR064262A1 (es) 2006-11-17 2007-11-16 Composiciones farmaceuticas liquidas que comprenden un compuesto bisfosfonato
ARP070105121A AR064263A1 (es) 2006-11-17 2007-11-16 Composiciones farmaceuticas que comprenden un compuesto bisfosfato

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP070105121A AR064263A1 (es) 2006-11-17 2007-11-16 Composiciones farmaceuticas que comprenden un compuesto bisfosfato

Country Status (9)

Country Link
US (2) US20080167271A1 (es)
EP (2) EP2114368A1 (es)
JP (2) JP2010510195A (es)
AR (2) AR064262A1 (es)
AU (2) AU2007321108A1 (es)
CA (2) CA2669489A1 (es)
IL (2) IL198678A0 (es)
TW (2) TW200831130A (es)
WO (2) WO2008059059A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2114368A1 (en) * 2006-11-17 2009-11-11 Besins Healthcare Pharmaceutical compositions comprising a bisphosphonate compound
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
ES2650665T3 (es) * 2009-07-31 2018-01-19 Grünenthal GmbH Método de cristalización y biodisponibilidad
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
WO2019232114A1 (en) * 2018-06-01 2019-12-05 The University Of North Carolina At Chapel Hill Injectable thermoresponsive hydrogels as a combinatory modality for controlled drug delivery, biomaterial implant and 3d printing bioink

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX21453A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
MX21452A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
JP3411690B2 (ja) * 1994-09-21 2003-06-03 帝人株式会社 局所投与用アレンドロン酸ナトリウム製剤
US6905701B2 (en) * 1997-06-11 2005-06-14 Umd, Inc. Formulations for transmucosal vaginal delivery of bisphosphonates
WO2000028982A2 (en) * 1998-11-19 2000-05-25 The Board Of Trustees For The University Of Arkansas Increasing bone strength with selected bisphosphonates
US20050074487A1 (en) * 1999-12-16 2005-04-07 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
JP2001253827A (ja) * 2000-02-15 2001-09-18 Pfizer Prod Inc 骨粗鬆症を治療するための組成物および方法
CA2407747C (en) * 2000-05-05 2008-03-11 F. Hoffmann-La Roche Ag Gel-like pharmaceutical composition for subcutaneous administration comprising bisphosphonic acids or their salts
KR100998856B1 (ko) * 2002-02-14 2010-12-08 규큐 야쿠힝 고교 가부시키가이샤 경피투여제제
JP4394888B2 (ja) * 2002-02-14 2010-01-06 救急薬品工業株式会社 経皮投与製剤
AU2004257674A1 (en) * 2003-07-11 2005-01-27 Macrochem Corporation Pharmaceutical compositions for topical application
MY141763A (en) * 2003-09-18 2010-06-30 Novartis Ag Pharmaceutical products comprising bisphosphonates
US20050119230A1 (en) * 2003-09-18 2005-06-02 Alexandra Glausch Pharmaceutical products comprising bisphosphonated
US20050244485A1 (en) * 2003-10-14 2005-11-03 Tsung-Min Hsu Transdermal administration of hydrophilic drugs using a basic permeation enhancer composition
EP2114368A1 (en) * 2006-11-17 2009-11-11 Besins Healthcare Pharmaceutical compositions comprising a bisphosphonate compound

Also Published As

Publication number Publication date
WO2008059060A1 (en) 2008-05-22
AU2007321109A1 (en) 2008-05-22
AU2007321108A1 (en) 2008-05-22
EP2088996A1 (en) 2009-08-19
US20080182822A1 (en) 2008-07-31
JP2010510194A (ja) 2010-04-02
JP2010510195A (ja) 2010-04-02
CA2669489A1 (en) 2008-05-22
TW200829282A (en) 2008-07-16
AU2007321109A2 (en) 2009-06-11
TW200831130A (en) 2008-08-01
CA2669488A1 (en) 2008-05-22
IL198678A0 (en) 2010-02-17
AR064263A1 (es) 2009-03-25
WO2008059059A1 (en) 2008-05-22
EP2114368A1 (en) 2009-11-11
US20080167271A1 (en) 2008-07-10
IL198698A0 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
AR064262A1 (es) Composiciones farmaceuticas liquidas que comprenden un compuesto bisfosfonato
JP5144277B2 (ja) 局所用生体付着性製剤
JP5731446B2 (ja) 局所用生体付着性製剤
AR063201A1 (es) Composiciones farmaceuticas de ropinirol y metodos de uso de las mismas
BRPI0822162B8 (pt) composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
BRPI0509708A (pt) composição de espuma de pimecrolimus contendo glicol de hexileno, opcionalmente álcool de oleil, dimetilisosorbìdeo e/ou triglicerìdeos de cadeia média
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
SG156624A1 (en) Organo-gel formulations for therapeutic applications
CL2013003163A1 (es) Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion.
EA200601253A1 (ru) Преимущественно линейная шипучая лекарственная форма фентанила для перорального применения и способы введения
RS51764B (en) TRANSDERMAL PHARMACEUTICAL COMPOSITION
UY29377A1 (es) Nuevas formilaciones líquidas de rotavirus, su preparación y sus usos.
BRPI0416260A (pt) método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica
JP2016510807A5 (es)
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
PE20080523A1 (es) Composiciones farmaceuticas topicas que comprenden un modificador de respuesta inmune
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
ES2137993T3 (es) La utilizacion de glicerina para moderar el aporte transdermico de medicamentos.
JP2006502166A5 (es)
ES2875381T3 (es) Formulación tópica
CL2004000899A1 (es) Composicion farmaceutica que contiene la sal sodica de telmisartan y un agente diuretico y procedimiento de preparacion.
CN1305460C (zh) 糖摄取的促进方法
PE20040548A1 (es) Lamina revestida de adhesivo para administracion dermica de un inhibidor selectivo de ciclooxigenasa-2
ES2732892T3 (es) Composición de tratamiento de hongos en las uñas

Legal Events

Date Code Title Description
FB Suspension of granting procedure